| Marcus James Barras, NP | |
|
2315 E Main St, New Iberia, LA 70560-4031 | |
| (337) 374-7620 | |
| (337) 374-7677 |
| Full Name | Marcus James Barras |
|---|---|
| Gender | Male |
| Speciality | Nurse Practitioner |
| Experience | 12 Years |
| Location | 2315 E Main St, New Iberia, Louisiana |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1295911642 | NPI | - | NPPES |
| 1040436 | Medicaid | LA |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Hulin Urgent Care Services Llc | 6800051285 | 108 |
News Archive
Iroko Pharmaceuticals, LLC, a global specialty pharmaceutical company dedicated to advancing the science of analgesia, announced that the U.S. Food and Drug Administration has accepted for review the Supplemental New Drug Application for ZORVOLEX (diclofenac), a lower dose nonsteroidal anti-inflammatory drug, for the proposed indication of treatment of osteoarthritis pain in adults. ZORVOLEX was approved by FDA in October 2013 for the treatment of mild to moderate acute pain in adults.
Infighting among Democrats over inclusion of a public plan in health care reform is turning disagreement between moderates and liberals into a "Democratic civil war" with outside groups taking part in the attacks, Politico reports.
An index that combines structure and function measurements can detect perimetric and preperimetric glaucoma more accurately, and can differentiate early, moderate, and advanced disease more successfully than systems that consider either variable alone, report researchers.
Researchers at the Cedars-Sinai Heart Institute have found in animals that infusing cardiac-derived stem cells with micro-size particles of iron and then using a magnet to guide those stem cells to the area of the heart damaged in a heart attack boosts the heart's retention of those cells and could increase the therapeutic benefit of stem cell therapy for heart disease.
Agios Pharmaceuticals, the leading biopharmaceutical company focused on discovering and developing novel drugs in the rapidly emerging field of cancer metabolism, today announced it has received two grants totaling more than $488,000 from the Qualifying Therapeutic Discovery Project (QTDP) Program.
› Verified 2 days ago
| Entity Name | Hulin Urgent Care Services Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1699049262 PECOS PAC ID: 6800051285 Enrollment ID: O20120710000537 |
News Archive
Iroko Pharmaceuticals, LLC, a global specialty pharmaceutical company dedicated to advancing the science of analgesia, announced that the U.S. Food and Drug Administration has accepted for review the Supplemental New Drug Application for ZORVOLEX (diclofenac), a lower dose nonsteroidal anti-inflammatory drug, for the proposed indication of treatment of osteoarthritis pain in adults. ZORVOLEX was approved by FDA in October 2013 for the treatment of mild to moderate acute pain in adults.
Infighting among Democrats over inclusion of a public plan in health care reform is turning disagreement between moderates and liberals into a "Democratic civil war" with outside groups taking part in the attacks, Politico reports.
An index that combines structure and function measurements can detect perimetric and preperimetric glaucoma more accurately, and can differentiate early, moderate, and advanced disease more successfully than systems that consider either variable alone, report researchers.
Researchers at the Cedars-Sinai Heart Institute have found in animals that infusing cardiac-derived stem cells with micro-size particles of iron and then using a magnet to guide those stem cells to the area of the heart damaged in a heart attack boosts the heart's retention of those cells and could increase the therapeutic benefit of stem cell therapy for heart disease.
Agios Pharmaceuticals, the leading biopharmaceutical company focused on discovering and developing novel drugs in the rapidly emerging field of cancer metabolism, today announced it has received two grants totaling more than $488,000 from the Qualifying Therapeutic Discovery Project (QTDP) Program.
› Verified 2 days ago
| Entity Name | Main Street Emergency Group Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1750796041 PECOS PAC ID: 4880917012 Enrollment ID: O20141219001279 |
News Archive
Iroko Pharmaceuticals, LLC, a global specialty pharmaceutical company dedicated to advancing the science of analgesia, announced that the U.S. Food and Drug Administration has accepted for review the Supplemental New Drug Application for ZORVOLEX (diclofenac), a lower dose nonsteroidal anti-inflammatory drug, for the proposed indication of treatment of osteoarthritis pain in adults. ZORVOLEX was approved by FDA in October 2013 for the treatment of mild to moderate acute pain in adults.
Infighting among Democrats over inclusion of a public plan in health care reform is turning disagreement between moderates and liberals into a "Democratic civil war" with outside groups taking part in the attacks, Politico reports.
An index that combines structure and function measurements can detect perimetric and preperimetric glaucoma more accurately, and can differentiate early, moderate, and advanced disease more successfully than systems that consider either variable alone, report researchers.
Researchers at the Cedars-Sinai Heart Institute have found in animals that infusing cardiac-derived stem cells with micro-size particles of iron and then using a magnet to guide those stem cells to the area of the heart damaged in a heart attack boosts the heart's retention of those cells and could increase the therapeutic benefit of stem cell therapy for heart disease.
Agios Pharmaceuticals, the leading biopharmaceutical company focused on discovering and developing novel drugs in the rapidly emerging field of cancer metabolism, today announced it has received two grants totaling more than $488,000 from the Qualifying Therapeutic Discovery Project (QTDP) Program.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Marcus James Barras, NP 2315 E Main St, New Iberia, LA 70560-4031 Ph: (337) 374-7620 | Marcus James Barras, NP 2315 E Main St, New Iberia, LA 70560-4031 Ph: (337) 374-7620 |
News Archive
Iroko Pharmaceuticals, LLC, a global specialty pharmaceutical company dedicated to advancing the science of analgesia, announced that the U.S. Food and Drug Administration has accepted for review the Supplemental New Drug Application for ZORVOLEX (diclofenac), a lower dose nonsteroidal anti-inflammatory drug, for the proposed indication of treatment of osteoarthritis pain in adults. ZORVOLEX was approved by FDA in October 2013 for the treatment of mild to moderate acute pain in adults.
Infighting among Democrats over inclusion of a public plan in health care reform is turning disagreement between moderates and liberals into a "Democratic civil war" with outside groups taking part in the attacks, Politico reports.
An index that combines structure and function measurements can detect perimetric and preperimetric glaucoma more accurately, and can differentiate early, moderate, and advanced disease more successfully than systems that consider either variable alone, report researchers.
Researchers at the Cedars-Sinai Heart Institute have found in animals that infusing cardiac-derived stem cells with micro-size particles of iron and then using a magnet to guide those stem cells to the area of the heart damaged in a heart attack boosts the heart's retention of those cells and could increase the therapeutic benefit of stem cell therapy for heart disease.
Agios Pharmaceuticals, the leading biopharmaceutical company focused on discovering and developing novel drugs in the rapidly emerging field of cancer metabolism, today announced it has received two grants totaling more than $488,000 from the Qualifying Therapeutic Discovery Project (QTDP) Program.
› Verified 2 days ago
Mr. Jonathan A Seghorn, PMHNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 806 Jefferson Ter, New Iberia, LA 70560 Phone: 337-365-4945 | |
Mrs. Alison T. Cantrall, NP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 2309 E Main St, Suite 301, New Iberia, LA 70560 Phone: 337-364-4415 Fax: 337-364-4495 | |
Allyson Hebert, FNP-C Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 2308 E Main St Ste B, New Iberia, LA 70560 Phone: 337-369-3683 Fax: 877-796-6140 | |
Ashley Robicheaux, NP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1110 E Saint Peter St, New Iberia, LA 70560 Phone: 337-364-1166 | |
Nichole Baucan, DNP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 806 Jefferson Ter, New Iberia, LA 70560 Phone: 337-365-4945 Fax: 337-367-3917 | |
Erin Elizabeth Perek, FNP-C Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 1110 E Saint Peter St, New Iberia, LA 70560 Phone: 337-364-1166 Fax: 337-364-7090 | |
Lisa L Freyou, ACNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 500 N Lewis St, Suite 100, New Iberia, LA 70563 Phone: 337-367-5200 Fax: 337-369-3074 |